Liver
Liver metastases
The most common tumours found in the liver: circulating cancer cells settle in it and grow as multiple masses. Colorectal adenocarcinoma is a typical source. Explore a real patient’s liver with three metastases, built from a published CT segmentation.
Causes and risk factors
- Spread of a primary carcinoma elsewhere, for example adenocarcinoma of the colon or carcinoma of the breast
- The liver is a common site because circulating tumour cells readily settle and grow there
Gross pathology
- Multiple masses of varying size scattered through the liver, rather than a single lesion.
- Larger masses often have central necrosis, which looks umbilicated (dimpled) beneath the capsule.
- With many metastases the liver can become markedly enlarged; on CT, the masses show darker areas of necrosis.
Under the microscope
- Tumour that resembles the primary (for example infiltrating ductal carcinoma from the breast) sits beside normal liver parenchyma.
- As the deposits enlarge they outgrow their blood supply, giving central necrosis.
- Immunohistochemistry helps to find the source: metastases are more likely to be CK-20 positive, whereas cholangiocarcinoma is CK-7 positive and CK-20 negative.
How it develops
- Tumour cells from a primary cancer enter the circulation.
- They lodge in the liver and grow into separate deposits, usually several at once.
- The deposits enlarge, outgrow their blood supply and become necrotic in the centre.
- Masses obstructing bile ducts raise the serum alkaline phosphatase, but because not all ducts are blocked, jaundice is usually absent.
Complications
- Raised alkaline phosphatase with little or no rise in bilirubin; transaminases usually not greatly raised
- Enlargement of the liver
- Liver failure is unlikely: enough liver function is usually retained
Investigations
- CT or MRI
- Multiple masses of varying size; maps their number and position for surgical planning.
- Liver function tests
- A raised alkaline phosphatase, often with a normal bilirubin, since enough liver remains.
- Tumour markers
- Carcinoembryonic antigen (CEA) is often raised with colorectal metastases and is used to follow the disease.
- Biopsy
- Confirms metastatic carcinoma; immunohistochemistry suggests the primary site.
Drug treatment
- Fluoropyrimidines (5-fluorouracil, capecitabine): Antimetabolites that starve dividing cells of thymidine for DNA; the backbone of chemotherapy for colorectal cancer, including cancer that has spread to the liver.
- Platinum compounds (cisplatin, carboplatin, oxaliplatin): Cytotoxic drugs that cross-link DNA; the backbone of chemotherapy for lung, testicular, gastric and colorectal cancers and osteosarcoma. Each has its own toxicity: cisplatin the kidney and ear, carboplatin the marrow, oxaliplatin the nerves.
- Topoisomerase inhibitors (etoposide, irinotecan): Drugs that trap DNA-cutting enzymes on DNA: etoposide (topoisomerase II) in testicular tumours and small cell lung cancer; irinotecan (topoisomerase I) in colorectal cancer.
Anatomy involved
Connected topics
Written from
- Robbins and Cotran Atlas of Pathology, 3rd ed., Ch. 8, The Liver and Biliary Tract, pp. 241–242, figs 8-54 to 8-57
Educational reference. Not medical advice, diagnosis or treatment.